Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Aug 19;99(4):611-5.
doi: 10.1038/sj.bjc.6604524. Epub 2008 Jul 29.

The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ

Affiliations

The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ

D Robinson et al. Br J Cancer. .

Abstract

Approximately 1 in every 600 women attending breast-screening programmes in the United Kingdom is diagnosed with breast carcinoma in situ (BCIS). However, there is little information on the occurrence of subsequent cancers (other than second breast cancers) in these women. We investigated the occurrence of invasive cancers in 12,836 women diagnosed with BCIS in southeast England between 1971 and 2003, using data from the Thames Cancer Registry. A greater than expected number of subsequent cancers was found for two sites: breast (standardised incidence ratio (SIR) 1.96; 95% confidence interval (CI) 1.79-2.14) and corpus uteri (SIR 1.42; 95% CI 1.11-1.78). For subsequent ipsilateral breast cancer in those treated with breast conservation, the excess was independent of the time since diagnosis of BCIS, whereas for subsequent contralateral breast cancer, there was a steady decline in excess over time. For subsequent uterine cancer, the excess became statistically significant only at >5 years after BCIS diagnosis, consistent with a treatment effect. This was further supported by Cox regression analysis: the risk of subsequent uterine cancer was significantly increased in women receiving hormonal therapy compared with those not receiving it, with a hazard ratio of 2.97 (95% CI 1.84-4.80).

PubMed Disclaimer

Similar articles

Cited by

References

    1. Andersson M, Storm HH, Mouridsen HT (1991) Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83: 1013–1017 - PubMed
    1. Atlante G, Pozzi M, Vincenzoni C, Vocaturo G (1990) Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol 37: 378–380 - PubMed
    1. Bijker N, Meijnen P, Peterse JL, Bogaerts J, van Hoorebeeck I, Julien J-P, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: ten-year results of European Organisation for Research and Treatment of Cancer Randomized phase III trial 10853 – a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24: 3381–3387 - PubMed
    1. Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, Aref A (2005) Bilateral risk for subsequent breast cancer after lobular carcinoma in situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 23: 5534–5541 - PubMed
    1. Claus EB, Stowe M, Carter D, Holford T (2003) The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. Breast 12: 451–456 - PubMed

MeSH terms